Nouvelle déclaration d'incident
No de la demande: 2020-2306
Numéro de référence du titulaire d'homologation: 2020-CA-000012
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: PRINCE EDWARD ISLAND
ARLA No d'homologation 25226 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard Flea and Tick Carpet Powder
Oui
Inconnu
Site: Res. - In Home / Rés. - à l'int. maison
Non
Autre
Cat / Chat
Domestic Mediumhair
1
Femme
10
10
lbs
Inconnu
>15 min <=2 hrs / >15 min <=2 h
>30 min <=2 hrs / >30 min <=2 h
Système
Unknown / Inconnu
Non
Non
Unknown/Inconnu
Contact treat.area/Contact surf. traitée
(p.ex. description des symptômes tels que la fréquence et la gravité
On 17-Jan-2020, a 10 year old, approximately 10 pound, neutered, female, Domestic Mediumhair cat, in unknown condition, with concomitant medical condition of fleas, had a secondary exposure to an unknown amount of Hartz UltraGuard Flea and Tick Carpet Powder (Phenothrin / N-Octyl-Bicycloheptene Dicarboximide) that had been applied to bedding and floors in the home. This was an extra label use as the cat was not kept out of the treated area. Approximately 1 hour post product application, the cat exhibited anorexia, lethargy and adipsia. The signs persisted at the time of the report. Bathing with liquid dish soap to remove the product in case contact occurred was recommended. Veterinary evaluation was also recommended. No further information was received in this case.
Modérée
Assessment: Mild GI irritation or upset may occur if the product is ingested either directly by a cat or from grooming it off of the fur, but prolonged decreased appetite and decreased drinking are not expected. Veterinary evaluation is warranted in this case as a precaution and to rule out other causes. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.